Proteomics International

By 2040, global esophageal cancer cases and deaths are projected to rise by over 60% compared to 2020. Yet in 2015, 59% of esophageal cancer cases in the UK were preventable. Recognizing early signs - like persistent heartburn 🔥- can lead to life-saving preventive action. #KnowTheSymptoms and understand why persistent heartburn could be #MoreThanJustHeartburn. At Proteomics International, we’re committed to advancing early detection solutions to improve outcomes for esophageal cancer. #esophagealcancer #OesophagealCancerAwarenessMonthUK #EarlyDetection #Barretts #SavesLives #Biomarkers #Diagnostics #PIQ #ASX https://lnkd.in/gSQFGxsx

Proteomics International’s (ASX:PIQ) Head of Clinical Studies, Dr Kirsten Peters, will be presenting at the Australian Gynaecological Endoscopy Society (AGES) Annual Scientific Meeting 2025 in Perth, Australia next week Dr Peters will be discussing “Plasma Protein Biomarkers as an Innovative Tool for the Non-Invasive Diagnosis of Endometriosis”, highlighting key findings from our latest publication on the development of PromarkerEndo. Date: Thursday, 27 February 2025 Session: Chairman’s Choice (Session 2), 9:30 am – 10:30 am If you're attending #AGESASM2025, don’t miss the session. View more about PromarkerEndo on our website - proteomics.com.au #Womenshealth #Endometriosis #Gynaecology #Diagnostics #Biomarkers #Diagnostics #PIQ #ASX

🧪 ⚡ 𝗣𝗞 𝗧𝗵𝗮𝘁 𝗪𝗼𝗿𝗸𝘀—𝗣𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 🧪 📊 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗸𝗶𝗻𝗲𝘁𝗶𝗰𝘀 𝗶𝘀𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗮 𝗰𝗵𝗲𝗰𝗸𝗽𝗼𝗶𝗻𝘁—𝘪𝘵’𝘴 𝘵𝘩𝘦 𝘬𝘦𝘺 𝘵𝘰 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘥𝘳𝘶𝘨 𝘴𝘢𝘧𝘦𝘵𝘺 𝘢𝘯𝘥 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺. 𝘈𝘵 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹, 𝗼𝘂𝗿 𝗜𝗦𝗢 𝟭𝟳𝟬𝟮𝟱-𝗮𝗰𝗰𝗿𝗲𝗱𝗶𝘁𝗲𝗱 𝗯𝗶𝗼𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗣𝗞 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝘦𝘯𝘴𝘶𝘳𝘦 𝘺𝘰𝘶 𝘨𝘦𝘵 𝘵𝘩𝘦 𝘥𝘢𝘵𝘢 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘮𝘰𝘷𝘦 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘸𝘪𝘵𝘩 𝘤𝘰𝘯𝘧𝘪𝘥𝘦𝘯𝘤𝘦. 🚀 𝗣𝗞 𝗶𝗻 𝗔𝗰𝘁𝗶𝗼𝗻: 𝘈𝘥𝘪𝘢𝘭 𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭𝘴' 𝘭𝘢𝘵𝘦𝘴𝘵 𝗣𝗞 𝘀𝘁𝘂𝗱𝘆 𝗳𝗼𝗿 𝗔𝗗𝟬𝟰 𝘤𝘰𝘯𝘧𝘪𝘳𝘮𝘦𝘥 𝘣𝘪𝘰𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘢𝘯𝘥 𝘥𝘰𝘴𝘦 𝘱𝘳𝘰𝘱𝘰𝘳𝘵𝘪𝘰𝘯𝘢𝘭𝘪𝘵𝘺—𝘱𝘢𝘷𝘪𝘯𝘨 𝘵𝘩𝘦 𝘸𝘢𝘺 𝘧𝘰𝘳 𝘍𝘋𝘈 𝘥𝘪𝘴𝘤𝘶𝘴𝘴𝘪𝘰𝘯𝘴 𝘢𝘯𝘥 𝘢 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝗣𝗵𝗮𝘀𝗲 𝟯 𝘁𝗿𝗶𝗮𝗹. 𝘛𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘗𝘒 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘮𝘢𝘬𝘦 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦! 𝗟𝗲𝘁’𝘀 𝗺𝗮𝗸𝗲 𝗣𝗞 𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝘆𝗼𝘂! #𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘰𝘬𝘪𝘯𝘦𝘵𝘪𝘤𝘴 #𝘋𝘳𝘶𝘨𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 #𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭𝘛𝘳𝘪𝘢𝘭𝘴 #𝘗𝘳𝘰𝘵𝘦𝘰𝘮𝘪𝘤𝘴𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭

World Kidney Day 2025 is just around the corner! On March 13, 2025, we will come together to raise awareness about kidney health. This year’s campaign focuses on a critical message: “Detect early, protect kidney health." 🩺 Did you know? 1 in 3 people with diabetes will develop chronic kidney disease (CKD). Diabetes-related kidney disease is a leading cause of kidney failure worldwide. Early detection and a healthy lifestyle can help prevent and manage kidney disease. Proteomics International (ASX:PIQ) supports the need for early detection of CKD in diabetes patients and is advancing the commercialisation of its innovative Promarker®D blood test, which can predict kidney decline up to four years before clinical symptoms appear. This World Kidney Day let’s spread the word and take action to prevent kidney disease! 🌍💙 Learn more about the 2025 campaign and how you can get involved: https://lnkd.in/g47ufF28 Learn more about PromarkerD here: promarkerd.com #AreYourKidneysOK #WorldKidneyDay #KidneyHealth #Diabetes #diabetickidneydisease #chronickidneydisease #PreventCKD #earlydetection #PromarkerD #Biomarkers #Prognotics #PIQ #ASX

Early Detection Saves Lives Esophageal cancer is one of the most aggressive cancers, often diagnosed too late when treatment options are limited. Recognizing symptoms early can make all the difference. Rachel Edge, a 38-year-old UK nurse, initially dismissed her persistent heartburn and chest pain. She later learned it was esophageal cancer. Rachel was lucky - but many others aren’t. At Proteomics International, we’re dedicated to developing innovative early detection solutions. Raising awareness and supporting prevention can help improve outcomes and save lives. Let’s take action this Esophageal Cancer Awareness & Prevention Month and make a difference together! #Esophagealcancer #Oesophagealcancerawarenessmonthuk #Earlydetection #Barretts #Saveslives #Biomarkers #Diagnostics #PIQ #ASX https://lnkd.in/gRrKNBCQ

The Australian Government has announced an investment of $573.3 million to enhance healthcare for women, with one of the focus areas on endometriosis and pelvic pain care. As part of this investment, 11 new endometriosis clinics will be opened, bringing the total nationwide to 33. This expansion aims to improve access to care for women experiencing endometriosis and pelvic pain, addressing long-standing gaps in healthcare. Proteomics International (ASX:PIQ) supports the need to reduce diagnostic wait times for women experiencing endometriosis-like symptoms. The PromarkerEndo blood test, currently in the late stages of development, offers potential for early screening to either rule in or rule out endometriosis, reducing the need for invasive surgery. By providing a quick, non-invasive blood test, PromarkerEndo aims to shorten diagnostic wait times, enabling women to access appropriate management and care options sooner. This could significantly improve the quality of life for women with endometriosis or similar conditions, offering a faster route to the support and treatment they need. These new initiatives and innovations mark a vital step forward in supporting women’s health. You can read more about the clinics here - https://lnkd.in/gMCP8yKB Visit our website to learn about PromarkerEndo – proteomics.com.au #WomensHealth #Endometriosis #Pelvicpain #Healthcare #PromarkerEndo

𝗝𝗼𝗶𝗻 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝘁 𝗕𝗶𝗼𝗔𝘀𝗶𝗮 𝟮𝟬𝟮𝟱! 🌍  #BioAsia2025 #LifeSciences #HealthcareInnovation #Biomarkers #Biosimilars #PKStudies #Diagnostics

February is Oesophageal Cancer Awareness Month in the UK, a vital time to highlight a condition that often goes unnoticed until it's too late. In the UK, around 8,000 people die from oesophageal cancer each year—about 22 deaths a day—with only 14% surviving longer than five years. However, 59% of cases are preventable. One key symptom to monitor is persistent heartburn, defined as heartburn occurring most days for three weeks or more. If you're experiencing frequent heartburn, please don't ignore it. Take time to evaluate your symptoms; it could empower you to protect your health. In our fight against oesophageal cancer, Proteomics International is committed to advancing innovative solutions for its early detection. We commend patient support groups like @heartburncanceruk and @gutscharityuk for their efforts in raising awareness that heartburn can indicate something serious. Together, we can promote early detection and save lives. #OesophagealCancerAwarenessMonthUK #barrettsoesophagus #heartburn #barretts #acidreflux #indigestion #CancerPrevention #saveslives #Biomarkers #PIQ #ASX https://lnkd.in/eeaKdtdK

𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹’𝘀 𝗣𝗞, 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 & 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 • 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗸𝗶𝗻𝗲𝘁𝗶𝗰𝘀 (𝗣𝗞) – LC-MS/MS assays for quantification of small molecule drugs in biological matrices • 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 & 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻– Powered by the 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿ᵀᴹ platform for discovery and validation of protein biomarkers • 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗧𝗲𝘀𝘁𝗶𝗻𝗴– Establish structural comparability to the reference biologic As 𝗮𝗻 𝗜𝗦𝗢 𝟭𝟳𝟬𝟮𝟱-𝗮𝗰𝗰𝗿𝗲𝗱𝗶𝘁𝗲𝗱 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 and an Australian 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗿 (𝗥𝗦𝗣𝟬𝟬𝟬𝟬𝟮𝟬), Proteomics International ensures 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆, 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆-𝗿𝗲𝗮𝗱𝘆 𝗱𝗮𝘁𝗮. With 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮’𝘀 𝗳𝗮𝘀𝘁 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀, 𝗥&𝗗 𝘁𝗮𝘅 𝗶𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀, 𝗮𝗻𝗱 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝗱𝗮𝘁𝗮, Proteomics International helps accelerate 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 & 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀. 📩 Connect with us to discuss your next study! #ClinicalTrials #Pharmacokinetics #Biomarkers #AustralianAdvantage #DrugDevelopment #ProteomicsInternational

Early Detection of CKD in Type 2 Diabetes: Improving Patient Outcomes   Chronic kidney disease (CKD) affects a significant number of individuals with type 2 diabetes, yet early detection often remains overlooked. This insightful discussion from experts highlights why identifying CKD in its earliest stages is critical for improving outcomes: By prioritising early diagnosis and treatment, we can significantly improve the quality of life for patients with type 2 diabetes. CKD management must be integrated at the point of care, working closely with GPs to ensure timely intervention Innovative solutions like Promarker®D could enable early clinical intervention, giving healthcare providers the tools they need to make a meaningful impact. Let’s prioritise kidney health through early detection and proactive care to ensure better outcomes for patients with type 2 diabetes! 👉 Listen to the full discussion - https://lnkd.in/g_ABaKJp PromarkerD.com #PIQ #PromarkerD #CKD #Type2Diabetes #T2D #EarlyDetection #KidneyHealth #PatientCare